CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.

Authors :: UCL - SSS/LDRI - Louvain Drug Research Institute
de Graan, Anne-Joy M
Elens, Laure
Sprowl, Jason A
Sparreboom, Alex
Friberg, Lena E
van der Holt, Bronno
de Raaf, Pleun J
de Bruijn, Peter
Engels, Frederike K
Eskens, Ferry A L M
Wiemer, Erik A C
Verweij, Jaap
Mathijssen, Ron H J
van Schaik, Ron H N
UCL - SSS/LDRI - Louvain Drug Research Institute
de Graan, Anne-Joy M
Elens, Laure
Sprowl, Jason A
Sparreboom, Alex
Friberg, Lena E
van der Holt, Bronno
de Raaf, Pleun J
de Bruijn, Peter
Engels, Frederike K
Eskens, Ferry A L M
Wiemer, Erik A C
Verweij, Jaap
Mathijssen, Ron H J
van Schaik, Ron H N
Source :: Clinical Cancer Research, Vol. 19, no.12, p. 3316-3324 (2013)
Publication Year :: 2013
Abstract: Paclitaxel is used for the treatment of several solid tumors and displays a high interindividual variation in exposure and toxicity. Neurotoxicity is one of the most prominent side effects of paclitaxel. This study explores potential predictive pharmacokinetic and pharmacogenetic determinants for the onset and severity of neurotoxicity.

Tools